Page 14 - Flipbook

Interim OS: PD-L1 status (Arm B vs Arm C)

100
90 PD-L1 IC0/1 PD-L1 IC2/3
80
70
(%) 60
50
OS 40

30
20 12.9 mo 13.5 mo 17.8 mo NE
10 (11.3, 15.0) (11.1, 16.4) (10.0, NE) (17.7, NE)
0
0 3 6 9 12 15 18 21 24 27 30 33 0 3 6 9 12 15 18 21 24 27 30 33
Months Months
No. at Risk
Atezo 272 210 175 152 124 85 48 28 11 NE NE NE 88 75 70 64 49 35 24 14 5 NE NE NE
Placebo + 274 246 212 173 116 73 41 21 10 2 NE NE 85 76 62 51 42 30 21 14 5 1 NE NE
plt/gem

Arm B Arm C Arm B Arm C
Atezo Placebo + plt/gem Atezo Placebo + plt/gem
(n = 272) (n = 274) (n = 88) (n = 85)
OS events, n (%) 158 (58) 156 (57) OS events, n (%) 33 (38) 42 (49)
Unstratified HR (95% CI) 1.07 (0.86, 1.33) Stratified HR (95% CI) 0.68 (0.43, 1.08)

Data cutoff 31 May 2019; median survival follow-up 11.8 months (all patients).

http://bit.ly/2Z1bPbD
IMvigor130—ESMO 2019 (LBA14): presented by Dr Enrique Grande